Immuneering Corporation is a clinical-stage biotechnology company focused on developing oncology therapeutics for patients with RAS- and RAF-mutated cancers. The company's lead program, IMM-1-104, is a dual-MEK inhibitor in Phase 1/2a development targeting multiple indications including pancreatic cancer, melanoma, and non-small cell lung cancer. A second candidate, IMM-6-415, is also in Phase 1/2a trials for solid tumors. The company was incorporated in Delaware in 2008 and maintains headquarters in Cambridge, Massachusetts.
As a development-stage company, Immuneering has not generated meaningful revenue from product sales. The organization currently operates with 54 full-time employees and remains dependent on capital financing to fund its clinical programs and operations. The company is listed on the Nasdaq exchange with a market capitalization of approximately $0.3 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.04 | $-2.04 | -8.5% | |
| 2023 | $-1.88 | $-1.88 | +1.1% | |
| 2022 | $-1.90 | $-1.91 | +22.8% | |
| 2021 | $-2.46 | $-2.46 | — |